End tb startergy full details for md exam answer 15 marks
Reading File
Finding Sources
Finding Sources
Searching the Web
WHO End TB Strategy 2035 pillars targets components details
Finding Sources
Reading Web Page
End TB strategy pillars components principles targets milestones
Reading File
Reading Web Page
End TB strategy pillars components principles DOTS STOP TB India national program
I now have comprehensive data from the WHO's official End TB Strategy document, Harrison's, and supporting sources. Let me compile a detailed, exam-ready 15-mark answer.
END TB STRATEGY — 15-Mark MD Exam Answer
Introduction
The End TB Strategy is a global tuberculosis elimination framework adopted by the World Health Assembly in May 2014 (Resolution WHA67.1), building on the earlier DOTS Strategy (1994–2005) and Stop TB Strategy (2006–2015). It was launched by WHO in 2015 as the post-2015 global TB strategy, aimed at eliminating TB as a public health crisis by 2035.
Vision: A world free of tuberculosis — zero deaths, disease, and suffering due to TB.
Goal: End the global TB epidemic.
Targets and Milestones
| Indicator | 2020 | 2025 | 2030 | 2035 |
|---|---|---|---|---|
| Reduction in TB deaths (vs. 2015 baseline of 1.3 million) | 35% | 75% | 90% | 95% |
| Reduction in TB incidence rate (vs. 2015 baseline of ~110/100,000) | 20% (<85/100,000) | 50% (<55/100,000) | 80% (<20/100,000) | 90% (<10/100,000) |
| Families facing catastrophic costs due to TB | — | Zero | Zero | Zero |
The 2035 targets represent incidence and mortality levels currently seen in low-TB-burden countries of North America, Western Europe, and the Western Pacific.
Framework Structure
The strategy has 3 Pillars, 10 Components, and 4 Underlying Principles.
The Four Underlying Principles
1. Government Stewardship and Accountability with Monitoring & Evaluation
- TB control spans health AND social sectors: finance, labour, trade, development
- Stewardship shared across central, provincial, and local government levels
- National TB Programs (NTPs) provide technical and strategic support
- Mandatory monitoring with standardized data collection
2. Strong Coalition with Civil Society Organizations and Communities
- Active involvement of TB-affected communities, NGOs, and patient groups
- Community engagement in case finding, treatment adherence, and advocacy
- Private sector engagement, especially in high-burden countries
3. Protection and Promotion of Human Rights, Ethics, and Equity
- TB disproportionately affects the poor, marginalized, and vulnerable populations
- Rights-based approach — equal access to diagnosis and treatment
- Reduction of stigma and discrimination against TB patients
- Address social determinants driving TB (poverty, malnutrition, overcrowding)
4. Adaptation of the Strategy and Targets at Country Level with Global Collaboration
- Each country adapts the framework to local epidemiology, resources, and health systems
- Milestones and targets set at national level, not just global
- International collaboration for research, funding, and technical assistance
The Three Pillars and Ten Components
PILLAR 1: Integrated, Patient-Centred Care and Prevention
This pillar builds directly on the DOTS and Stop TB Strategy. It encompasses all core health service functions for TB care and prevention.
Component A — Early Diagnosis of TB, Including Universal Drug-Susceptibility Testing (DST), and Systematic Screening of Contacts and High-Risk Groups
- Early and accurate diagnosis is the cornerstone of TB control
- Universal DST at diagnosis to detect drug resistance (especially RR-TB, MDR-TB, XDR-TB)
- Systematic contact tracing around index cases
- Targeted screening of high-risk groups: PLHIV, healthcare workers, prisoners, migrants, close contacts, malnourished individuals, diabetics, immunosuppressed patients
- Use of molecular rapid diagnostics (Xpert MTB/RIF, LF-LAM)
- Active case finding in high-burden communities
Component B — Treatment of All People with TB, Including Drug-Resistant TB, and Patient Support
- Universal access to quality-assured TB treatment, including MDR-TB and XDR-TB
- WHO-recommended standard regimens (2HRZE/4HR for drug-sensitive TB)
- Shorter, safer MDR-TB regimens (BPaL/BPaLM regimens with bedaquiline, pretomanid, linezolid)
- Patient support systems: social support, nutritional supplements, incentives, enablers
- Differentiated care: ambulatory-based, patient-centred models replacing prolonged hospitalization
- Psychosocial support and patient empowerment
- Monitoring of treatment outcomes (cure, treatment completion, default, death, failure)
Component C — Collaborative TB/HIV Activities, and Management of Comorbidities
- TB is the leading cause of death in PLHIV — coordinated response is essential
- Provider-initiated HIV testing for all TB patients
- Antiretroviral therapy (ART) for all HIV-TB co-infected patients regardless of CD4 count
- Co-trimoxazole preventive therapy (CPT) for all TB-HIV patients
- TB preventive therapy (TPT/IPT) for all HIV-positive individuals
- Screening and management of comorbidities: diabetes mellitus, malnutrition, smoking, alcohol use, silicosis, COPD
- Integrated service delivery (TB/HIV clinics, diabetic-TB clinics)
Component D — Preventive Treatment of Persons at High Risk, and Vaccination Against TB
- TB Preventive Therapy (TPT) for:
- PLHIV
- Household contacts of bacteriologically confirmed TB cases (especially children <5 years)
- Other high-risk groups (immunosuppressed, recent TST/IGRA converters)
- Standard TPT regimens: 6H (6 months INH), 3HP (3 months weekly INH+Rifapentine), 4R (4 months rifampicin)
- BCG vaccination: continue for all neonates in high-burden settings
- Pipeline for new TB vaccines — critical for elimination post-2025
PILLAR 2: Bold Policies and Supportive Systems
Component A — Political Commitment with Adequate Resources for TB Care and Prevention
- Domestic government financing as primary funding source
- Sustained international donor support (Global Fund, USAID, PEPFAR)
- TB action plans, legislation, and regulatory frameworks
- Accountability mechanisms and parliamentary oversight
Component B — Engagement of Communities, Civil Society Organizations, and Public and Private Care Providers
- Private sector engagement: large proportion of TB patients seek care in private sector first
- Public-Private Mix (PPM) — notify all diagnosed TB cases, quality treatment
- Social contracting, accreditation, and incentives for private providers
- Community volunteers for contact tracing and treatment support (DOTS supporters)
Component C — Universal Health Coverage (UHC) Policy, and Regulatory Frameworks for Case Notification, Vital Registration, Quality and Rational Use of Medicines, and Infection Control
- Mandatory TB notification of all diagnosed cases (public and private)
- Robust vital registration and surveillance systems
- Quality-assured TB diagnostics and drugs (national formulary, pharmacovigilance)
- Infection control (IPC) in healthcare facilities: natural ventilation, UV lamps, N95 respirators for HCWs, separation of infectious TB cases
- Rational use of medicines to prevent drug resistance
Component D — Social Protection, Poverty Alleviation, and Actions on Other Determinants of TB
- Address social determinants: poverty, malnutrition, overcrowding, indoor air pollution
- Social cash transfers, housing support, nutritional support for TB patients
- Addressing risk factors: smoking cessation, alcohol programs, diabetes management
- Integration with social protection schemes (food security, livelihood programs)
- Targeting the most vulnerable: indigenous communities, migrants, prisoners
PILLAR 3: Intensified Research and Innovation
This pillar is described as critical to break the trajectory of the TB epidemic — without new tools, the 2035 targets cannot be achieved.
Component A — Discovery, Development, and Rapid Uptake of New Tools, Interventions, and Strategies
- New TB vaccines: need vaccine with >50% efficacy in adolescents/adults (pipeline: M72/AS01E, VPM1002)
- New rapid diagnostics: point-of-care test for active TB and LTBI (molecular, immunological)
- New drug regimens: shorter (≤4 months), safer regimens for drug-sensitive and drug-resistant TB
- Currently: BPaL, BPaLM (bedaquiline + pretomanid + linezolid ± moxifloxacin)
- Short course regimens: STREAM trial, ZeNix, TB-PRACTECAL
- TB preventive therapy innovations: shorter, simpler, safer regimens
Component B — Research to Optimize Implementation and Impact and Promote Innovations
- Health systems research: implementation, scale-up, cost-effectiveness
- Operational research to identify and overcome barriers
- Social science research on stigma, behavior, and community engagement
- Research equity: capacity building in high-burden, low-income countries
- Accelerated regulatory pathways for new TB diagnostics and drugs
Key Enabling Features
| Feature | Details |
|---|---|
| Adopted by | World Health Assembly, May 2014 |
| Launched | 2015 (operational 2016 onwards) |
| Built on | DOTS (1994–2005) → Stop TB Strategy (2006–2015) → End TB (2015–2035) |
| UN SDG alignment | SDG 3.3: End TB epidemic by 2030 |
| Funding | Global Fund, PEPFAR, domestic government budgets |
| 2023 UN political declaration target | 90% treatment coverage by 2027 (45 million treated 2023–2027) |
India-Specific Context (Nikshay Portam / National TB Elimination Program)
India adopted the End TB Strategy under the National TB Elimination Program (NTEP), formerly RNTCP. Key India-specific milestones:
- Target: Eliminate TB by 2025 (ahead of global 2030 goal), declared by Prime Minister Modi
- Nikshay Poshan Yojana: ₹500/month direct benefit transfer (nutritional support) to all notified TB patients
- Pradhan Mantri TB Mukt Bharat Abhiyaan (PMTBMBA): community adoption of TB patients
- Universal DST: Xpert and LPA (Line Probe Assay) for all diagnosed cases
- Mandatory TB notification for all public and private sector providers
Evolution of TB Control Strategies (Historical Context)
| Strategy | Period | Core Feature |
|---|---|---|
| DOTS | 1994–2005 | 5 components: political commitment, sputum microscopy, short-course chemotherapy, drug supply, recording/reporting |
| Stop TB Strategy | 2006–2015 | Expanded DOTS to address MDR-TB, HIV-TB, health system strengthening |
| End TB Strategy | 2015–2035 | 3 pillars, 10 components, 4 principles; targets 95% mortality reduction and 90% incidence reduction by 2035 |
Summary (Examination Points)
- Adopted: WHA, May 2014; operational from 2016
- Vision: Zero TB deaths, disease, suffering
- Goal: End global TB epidemic
- 4 Principles: Government stewardship; Civil society coalition; Human rights & equity; Country-level adaptation
- 3 Pillars: Patient-centred care & prevention | Bold policies & systems | Research & innovation
- 10 Components: 4 under Pillar 1, 4 under Pillar 2, 2 under Pillar 3
- 2035 Targets: 95% reduction in deaths; 90% reduction in incidence; Zero catastrophic costs
- Milestone 2025: 75% mortality reduction; 50% incidence reduction
- Key innovations required: New vaccine, new rapid POC test, new short regimens
- India target: TB elimination by 2025 under NTEP
References:
- WHO End TB Strategy: Global strategy and targets for TB prevention, care and control after 2015. WHO, 2015.
- Harrison's Principles of Internal Medicine, 22nd Ed., 2025 — "Principles of TB Control" (p. 1446)
- Goldman-Cecil Medicine, 2nd Vol. — Epidemiology of TB (WHO End TB declaration)
- Implementing the End TB Strategy: The Essentials, WHO 2022 Update
This is a shared conversation. Sign in to Orris to start your own chat.